With OWS it's going to be a lot of paperwork and there will be strings attached. Increasing production over what we already have for this year is unlikely anyway. We only have two production facilities approved. AGC has limited production capabilities and Samsung has the bioreactors we don't already have scheduled allocated elsewhere. If we had additional money in February or at the beginning of March we could have had additional reactors scheduled. With no money and no guarantee of FDA approval it would have been a bad business decision to schedule them.